Organic Letters
Letter
(17) (a) Inami, T.; Baba, Y.; Kurahashi, T.; Matsubara, S. Org. Lett.
2011, 13, 1912−1915. (b) Inami, T.; Kurahashi, T.; Matsubara, S. Org.
Lett. 2014, 16, 5660−5662.
( N R F - 2 0 1 5 R 1 A 5 A 1 0 0 8 9 5 8 a n d N R F -
2015R1C1A2A01053504).
(18) Shen, C.; Spannenberg, A.; Wu, X.-F. Angew. Chem., Int. Ed.
2016, 55, 5067−5070.
REFERENCES
■
(19) Among other unidentifiable products, the formation of hydrated
products was observed.
(1) For reviews, see: (a) Pohland, A. E.; Benson, W. R. Chem. Rev.
1966, 66, 161−197. (b) Gooßen, L. J.; Rodríguez, N.; Gooßen, K.
Angew. Chem., Int. Ed. 2009, 48, 9592−9594.
(2) For recent examples, see: (a) Gandeepan, P.; Parthasarathy, K.;
Su, T.-H.; Cheng, C.-H. Adv. Synth. Catal. 2012, 354, 457−468.
́
(b) Cano, R.; Yus, M.; Ramon, D. J. Tetrahedron 2013, 69, 7056−
(20) The formation of allenyl ketone intermediates was not observed
upon treating the purified (E)-3b with Et3N. Instead, the formation of
chromenone 4b was observed from (E)-3b in 85% yield.
(21) The use of AlCl3 did not effect the cyclization of alkynone 3q
under the method A conditions.
(22) The fact that the soft α-vinyl enolization of (E)-3b prompts the
direct formation of chromenone 4b suggests that the intermediate,
hydroxyallenyl ketone, might readily undergo the cyclization to
chromenone under slightly basic/neutral conditions. The β-chlor-
ovinyl ketones derived from 1,2-dialkylalkynes failed to provide (thio)
chromenones, possibly due to the lack of α-hydrogen for the soft vinyl
enolization to give allenyl ketone intermediates.
7065. (c) Iwai, T.; Fujihara, T.; Terao, J.; Tsuji, Y. J. Am. Chem. Soc.
2012, 134, 1268−1274. (d) Kashiwabara, T.; Tanaka, M. Adv. Synth.
Catal. 2011, 353, 1485−1490. (e) Wang, B.; Wang, S.; Li, P.; Wang, L.
Chem. Commun. 2010, 46, 5891−5893. (f) See ref1a.
(3) (a) Benson, W. R.; Pohland, A. E. J. Org. Chem. 1964, 29, 385−
391. (b) Oh, K.; Kim, H.; Cardelli, F.; Bwititi, T.; Martynow, A. M. J.
Org. Chem. 2008, 73, 2432−2434.
(4) Kim, H. Y.; Li, J.-Y.; Oh, K. J. Org. Chem. 2012, 77, 11132−
11145.
(5) For the previous contributions from our group, see: (a) Kim, H.
Y.; Li, J.-Y.; Oh, K. Angew. Chem., Int. Ed. 2013, 52, 3736−3740.
(b) Kim, H. Y.; Rooney, E. O.; Meury, R. P.; Oh, K. Angew. Chem., Int.
Ed. 2013, 52, 8026−8030. (c) Kim, H. Y.; Oh, K. Org. Lett. 2014, 16,
5934−5936. (d) Kim, H. Y.; Lee, S.; Kim, S.; Oh, K. Org. Lett. 2015,
17, 450−453. (e) Kim, H. Y.; Oh, K. Org. Lett. 2015, 17, 6254−6257.
(6) For selected reviews, see: (a) Kosmider, B.; Osiecka, R. Drug Dev.
Res. 2004, 63, 200−211. (b) Teillet, F.; Boumendjel, A.; Boutonnat, J.;
Ronot, X. Med. Res. Rev. 2008, 28, 715−745. (c) Talhi, O.; Silva, A. M.
S. Curr. Org. Chem. 2012, 16, 859−896. (d) Kumazawa, Y.; Takimoto,
H.; Matsumoto, T.; Kawaguchi, K. Curr. Pharm. Des. 2014, 20, 857−
863.
(7) For selected examples, see: (a) Okombi, S.; Schmidt, J.; Mariotte,
A.; Perrier, E.; Boumendjel, A. Chem. Pharm. Bull. 2005, 53, 1460−
1462. (b) Chee, C. F.; Buckle, M. J. C.; Rahman, N. A. Tetrahedron
Lett. 2011, 52, 3120−3123. (c) Zhao, J.; Zhao, Y.; Fu, H. Org. Lett.
2012, 14, 2710−2713.
(8) For selected examples, see: (a) Lorenz, M.; Kabir, M. S.; Cook, J.
M. Tetrahedron Lett. 2010, 51, 1095−1098. (b) Du, Z.; Ng, H.; Zhang,
K.; Zeng, H.; Wang, J. Org. Biomol. Chem. 2011, 9, 6930−6933.
(c) Sashidhara, K. V.; Kumar, M.; Kumar, A. Tetrahedron Lett. 2012,
53, 2355−2359.
(9) For a recent reviews, see: (a) Gaspar, A.; Matos, M. J.; Garrido, J.;
Uriarte, E.; Borges, F. Chem. Rev. 2014, 114, 4960−4992. (b) Tome, S.
M.; Silva, A. M. S.; Santos, C. M. M. Curr. Org. Synth. 2014, 11, 317−
341.
(10) For selected examples, see: (a) Zhou, C.; Dubrovsky, A. V.;
Larock, R. C. J. Org. Chem. 2006, 71, 1626−1632. Using TfOH, see:
(b) Yoshida, M.; Fujino, Y.; Doi, T. Org. Lett. 2011, 13, 4526−4529.
(11) Chai, G.; Qiu, Y.; Fu, C.; Ma, S. Org. Lett. 2011, 13, 5196−5199.
(12) For selected examples, see: (a) Kumar, P.; Bodas, M. S. Org.
Lett. 2000, 2, 3821−3823. (b) Das, J.; Ghosh, S. Tetrahedron Lett.
2011, 52, 7189−7194.
(13) For selected examples, see: (a) Kim, K.; Choe, H.; Jeong, Y.;
Lee, J. H.; Hong, S. Org. Lett. 2015, 17, 2550−2553. (b) Lee, J.; Yu, J.;
Son, S. H.; Heo, J.; Kim, T.; An, J.-Y.; Inn, K.-S.; Kim, N.-J. Org.
Biomol. Chem. 2016, 14, 777−784.
(14) For selected examples, see: (a) Liang, B.; Huang, M.; You, Z.;
Xiong, Z.; Lu, K.; Fathi, R.; Chen, J.; Yang, Z. J. Org. Chem. 2005, 70,
6097−6100. (b) Awuah, E.; Capretta, A. Org. Lett. 2009, 11, 3210−
3213. (c) Yang, Q.; Alper, H. J. Org. Chem. 2010, 75, 948−950.
(15) For examples, see: (a) Wang, H.-K.; Bastow, K. F.; Cosentino,
L. M.; Lee, K.-H. J. Med. Chem. 1996, 39, 1975−1980.
(b) Dekermendjian, K.; Kahnberg, P.; Witt, M.-R.; Sterner, O.;
Nielsen, M.; Liljefors, T. J. Med. Chem. 1999, 42, 4343−4350.
(c) Kataoka, T.; Watanabe, S.; Mori, E.; Kadomoto, R.; Tanimura, S.;
Kohno, M. Bioorg. Med. Chem. 2004, 12, 2397−2407.
(16) Fuchs, F. C.; Eller, G. A.; Holzer, W. Molecules 2009, 14, 3814−
3832.
D
Org. Lett. XXXX, XXX, XXX−XXX